Uhrenholt, Line http://orcid.org/0000-0002-4047-7175
Sørensen, Mads E. R.
Lauridsen, Karen B. http://orcid.org/0000-0003-2187-8288
Duch, Kirsten http://orcid.org/0000-0002-5984-5134
Dreyer, Lene http://orcid.org/0000-0002-5156-2922
Christensen, Robin http://orcid.org/0000-0002-6600-0631
Hauge, Ellen-Margrethe http://orcid.org/0000-0003-2562-9174
Loft, Anne Gitte http://orcid.org/0000-0001-6374-841X
Rasch, Mads N. B.
Horn, Hans Christian http://orcid.org/0000-0002-0792-0366
Taylor, Peter C. http://orcid.org/0000-0001-7766-6167
Nielsen, Kaspar R. http://orcid.org/0000-0003-4406-9643
Kristensen, Salome http://orcid.org/0000-0001-5812-5234
Funding for this research was provided by:
The Danish Regions Medicine Grants (16/2885)
Gigtforeningen (R188-A6592)
Manufacturer Vilhelm Pedersen and Wife’s Grant after recommendation from The Novo Nordisk Foundation (0060515)
Aase og Ejnar Danielsens Fond (19-10-0285)
The Health Science Research Fund of the North Denmark Region (2016-017615)
The Department of Rheumatology at Aalborg University Hospital
Oak Foundation (OCAY-18-774-OFIL)
Aalborg University Hospital
Article History
Received: 3 June 2024
Accepted: 10 July 2024
First Online: 24 July 2024
Declarations
:
: LU has received speakers fee from AbbVie, Eli-Lilly, Janssen, and Novartis; travel expenses from Abbvie (All unrelated to this manuscript); KBL has received speakers fee from Thermo Fisher Scientific (Unrelated to this manuscript); LD has received speakers fee from Eli Lilly, Galderma, and Janssen, research grants to Aalborg University Hospital from BMS and AbbVie (All unrelated to this manuscript); EMH has received fees for speaking and/or consulting from Novo, and Novartis; research grants to Aarhus University Hospital from Independent Research Fund Denmark, Novo Nordic Foundation, Danish Rheumatism Association, Aarhus University, Danish Regions Medicine Grants, Galapagos, and AbbVie; travel expenses from Pfizer, Sobi, and AbbVie; has been principal investigator in trials by SynACT Pharma, and involved as site principal investigator in trials by AbbVie, Novartis, Novo Nordisk, and Sanofi (All unrelated to this manuscript); AGL has received speakers fee from MSD, Novartis and Pfizer, and participated on advisory boards by Eli-Lilly, Janssen, Novartis, and UCB (All unrelated to this manuscript); MNBR has received speakers fee from Sobi Scientific (Unrelated to this manuscript); HCH has participated on an advisory board by Janssen Scientific (Unrelated to this manuscript); PCT has received consulting fees from AbbVie, Biogen, Eli-Lilly, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Sanofi, and UCB, research grants from Galapagos (All unrelated to this manuscript); MERS, KD, RC, KRN, and SK declare that they have no competing interests.
: No external editing support was used in this work. No part of this manuscript is copied, published, or archived elsewhere in whole or in part in any languages apart from the congress abstract publication.
: The North Denmark Region Committee on Health Research Ethics (N-20170073), the Danish Medicine Agency (2017091722), and the Danish Data Protection Agency (2017-194) gave approval for the study. BIODOPT complied with the Declaration of Helsinki and was on December 21, 2017, registered at EudraCT (2017-001970-41).
: All participants gave written informed consent before enrolment.